Corvus Pharmaceuticals Business Summary

Corvus Pharmaceuticals, Inc. (CRVS) is a clinical-stage biopharmaceutical company that operates on a research-and-development business model, currently generating value through the advancement of its proprietary pipeline rather than product sales. The company focuses on small molecule and antibody candidates that modulate the immune system to treat cancer and autoimmune diseases, with revenue potential tied to future licensing agreements, milestone payments, and commercialization of its lead candidate, soquelitinib (an ITK inhibitor). Its primary business segments are divided into Oncology, targeting T-cell lymphomas, and Immunology, focusing on atopic dermatitis and other inflammatory conditions. Corvus competes directly with firms such as Arcus Biosciences, ImmunityBio, Kymera Therapeutics, and Protagonist Therapeutics, positioning itself as a specialist in novel ITK inhibition and adenosine pathway modulation within the broader immunotherapy market. The leadership team is anchored by Co-Founder, President, and CEO Richard A. Miller, M.D., a prominent figure in oncology who previously co-founded IDEC Pharmaceuticals (now Biogen) and served as CEO of Pharmacyclics, where he led the development of the blockbuster drug ibrutinib. He is joined by CFO Leiv Lea, who also served as CFO at Pharmacyclics, and Chief Business Officer Jeffrey Arcara, who brings over 30 years of commercial strategy experience from major biopharma firms. The company’s strategic direction is further supported by a high-pedigree board including David Moore (EVP at Novo Nordisk) and Ian T. Clark (former CEO of Genentech). Notable institutional backers include OrbiMed Advisors, Point72 Asset Management, and BlackRock, reflecting strong institutional confidence in the company’s scientific platform.